Roche
Search results
Novartis. Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
The Novartis Commitment to Patients and Caregivers. Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Learn More.
Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group and owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered...
Mar 15, 2024 · SINGAPORE - Swiss pharmaceutical giant Novartis is spending US$256 million (S$342.3 million) to expand its biopharmaceutical manufacturing plant here. The enlarged facility is expected to be ...
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Mar 15, 2024 · Novartis breaks ground on $256 million expansion of biopharmaceutical manufacturing plant in Singapore. Investment focuses on deploying digital and automation solutions to boost productivity, efficiency, and workforce skills.
Search for careers at Novartis and discover our diverse and inclusive teams where we collaborate to bring innovative products to life.
Mar 15, 2024 · Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market. Set to generate 100 high skilled employment...
Mar 15, 2024 · SWISS biopharma giant Novartis has invested US$256 million to expand its biopharmaceutical manufacturing plant in Singapore. The expanded site will focus on manufacturing therapeutic antibody drugs.
